ANANDA Scientific Inc., a biotech pharma company, and the New York University (NYU) Grossman School of Medicine announced a second clinical trial to evaluate the effects of CBD in proprietary ANANDA’s delivery technology on test subjects who treat spinal pain with opioids. The Colorado-based company said initial studies show ANANDA’s Liquid Structure CBD application, licensed from Lyotropic Delivery Systems Ltd., Israel, can help to reduce opioid intake for patients who suffer such chronic pain. An Investigational New Drug application for Liquid Structure has been approved by the U.S. Food and Drug Administration. The trial is led by Stephen Ross, MD, Associate Professor of Psychiatry and Director, NYU Addictive Disorders and Experimental Therapeutics Research Laboratory. Funding for the trial is from the National Institute on Drug Abuse, with additional support from ANANDA Scientific.
Bio-tech firm announces CBD trials
Like HempToday? How you can support us
Your donations help us to keep HempToday open for all readers, regardless of what they can afford to pay. Through this “information equality” we're able to support hemp entrepreneurs and stakeholders all over the world by keeping a spotlight on hemp and all the promise it offers for economic development and healing our planet.
